SaraMichelleFedericoMD

Pediatric Hematology & Oncology • Memphis, TN

Physician

Join to view full profile

Dr. Federico is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Federico's full profile

Already have an account?

Office
262 Danny Thomas Pl
Memphis, TN 38105
Phone+1 901-595-3300

Fax+1 901-521-9005

Education & Training

University of TennesseeFellowship, Pediatric Hematology/Oncology, 2007 - 2011
Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 2003 - 2006
Virginia Commonwealth University School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2004 - Present
TN State Medical License 2006 - 2026

Clinical Trials

Molecular Analysis Of Solid Tumors Start of enrollment: 2010 Feb 10
Recruiting
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Start of enrollment: 2019 Mar 04
Active, not recruiting
Phase 2
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Start of enrollment: 2021 Jun 09
Active, not recruiting
Phase 1, Phase 2
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Start of enrollment: 2024 Jul 01
Not yet recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

47 citations
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
Wayne L Furman, Beth McCarville, Barry L Shulkin, Andrew Davidoff, Matthew Krasin
Journal of Clinical Oncology. 2022-02-01
102 citations
A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Sara M. Federico, M. Beth McCarville, Barry L. Shulkin, Paul M. Sondel, Jacquelyn A. Hank
Clinical Cancer Research. 2017-11-01
51 citations
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.
Wayne L. Furman, Sara M. Federico, Mary Beth McCarville, Barry L. Shulkin, Andrew M. Davidoff
Clinical Cancer Research. 2019-11-01

Journal Articles

Case Report: Management Approach and Use of Extracorporeal Membrane Oxygenation for Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Cell Transplant
Sara Federico, Amr Qudeimat, Frontiers in Pediatrics

Press Mentions

$First Successful Treatment of Pediatric High-Risk Refractory Neuroblastoma with PARP Inhibition$
First Successful Treatment of Pediatric High-Risk Refractory Neuroblastoma with PARP InhibitionAugust 15th, 2024
'Bridge' Therapy May Benefit Some Kids with High-Risk NeuroblastomaJune 22nd, 2022
Findings About Children’s Solid Tumors Are Sparking New TherapiesApril 9th, 2019
Join now to see all